MAPT and Cognitive impairment: Indeed, PGE2 levels were increased in the substantia nigra [143] and the CSF of PD patients with mild cognitive impairment and dementia although, in the first study, it was measured by enzyme immunoassay, whereas in the second study, its levels were not associated with elevated total-tau, phosphorylated-tau, or other inflammatory mediators [144].